CALIDI BIOTHERAPEUTICS INC (CLDI) Stock Price, Quote, News and Overview
NYSEARCA:CLDI - American Stock Exchange - US3207033099 - Common Stock
CLDI Quote and Key Statistics
CALIDI BIOTHERAPEUTICS INC
NYSEARCA:CLDI (1/22/2025, 8:04:02 PM)
After market: 0.8118 +0.05 (+6.26%)0.764
-0.07 (-8.46%)
CLDI Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -387.44% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CLDI Performance and Technical Analysis
CLDI Ownership and Analysts
CLDI Latest News and Analysis
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.
Get insights into the top gainers and losers of Friday's pre-market session.
Thursday's after hours session: top gainers and losers
Thursday's after hours session: top gainers and losers
Stay updated with the stocks that are on the move in today's after-hours session.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company...
Why Calidi Biotherapeutics (CLDI) Stock Is Down 30%
Calidi Biotherapeutics shares are trading lower by 32% during Friday's session. The company priced its public offering of 5 million shares of common stock at $0.85 per share.
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage...
About CLDI
Company Profile
Calidi Biotherapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 41 full-time employees. The company went IPO on 2021-09-10. Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The firm's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.
Company Info
CALIDI BIOTHERAPEUTICS INC
4475 Executive Drive, Suite 200
San Diego CALIFORNIA US
Employees: 41
Company Website: https://www.calidibio.com/
Investor Relations: http://calidibio.com/investors/
Phone: 18587949600
CLDI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.74 | 299.00B | ||
| AMGN | AMGEN INC | 14.23 | 146.98B | ||
| GILD | GILEAD SCIENCES INC | 21 | 115.95B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839.22 | 110.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.97 | 74.73B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.38B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.75B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.66B | ||
| NTRA | NATERA INC | N/A | 22.70B | ||
| BIIB | BIOGEN INC | 8.74 | 20.80B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.34B |